This trial is looking at whether it's possible to generate an investigational vaccine for patients with brain cancer who have already started chemotherapy.
1 Primary · 0 Secondary · Reporting Duration: Leukapheresis to investigational product release date or up to 6 weeks
10 Total Participants · 1 Treatment Group
Primary Treatment: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF · No Placebo Group · Phase 1
Age 18 - 90 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: